Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 13/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | KDM5C | P41229 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13428779 | 0.93 | CYP1A2 (0.47) | KDM4EMEN1GAAKMT2AL3MBTL1 | |
| SCHEMBL3222737 | 0.84 | ALDH1A1 (0.52) | KMT2AL3MBTL1P2RY12CYP2C9CYP2C19 | |
| SCHEMBL13428793 | 0.82 | L3MBTL1 (0.44) | KMT2AL3MBTL1P2RY12CYP2C9CYP2C19 | |
| SCHEMBL1179270 | 0.80 | L3MBTL1 (0.46) | KMT2AL3MBTL1P2RY12CYP2C9CYP2C19 | |
| SCHEMBL13428784 | 0.79 | MAPT (0.43) | MEN1KMT2AL3MBTL1P2RY12 | |
| SCHEMBL3224541 | 0.79 | P2RY12 (0.48) | KDM4EMEN1KMT2AL3MBTL1P2RY12 | |
| SCHEMBL13428783 | 0.78 | P2RY12 (0.47) | KDM4EMEN1KMT2AL3MBTL1P2RY12 | |
| SCHEMBL3220751 | 0.78 | STK17B (0.50) | KDM4EL3MBTL1P2RY12 | |
| SCHEMBL3227719 | 0.78 | L3MBTL1 (0.47) | L3MBTL1P2RY12CYP2C9CYP2C19 | |
| SCHEMBL3217492 | 0.78 | P2RY12 (0.48) | MEN1KMT2AL3MBTL1P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | HDAC1, HDAC11, HDAC2 | KDM4E 253/4885MEN1 2025/4885GAA 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.